Bayer Senior Executive to Lead World Self-Medication Industry: Global Self-Medication Industry Association Elects Bayer

  Bayer Senior Executive to Lead World Self-Medication Industry: Global
  Self-Medication Industry Association Elects Bayer HealthCare’s Erica Mann as
  Incoming Chair

Business Wire

LEVERKUSEN, Germany -- September 25, 2013

The Board of Directors of the World Self-Medication Industry (WSMI) -- the
global industry trade association for non-prescription drugs and dietary
supplements -- today has named as its Chair-Elect Erica Mann, member of the
Bayer HealthCare Executive Committee and president of Bayer HealthCare’s
Global Consumer Care division. Mann will succeed current Chair Dr. Zhenyu Guo,
CEO, Dihon Pharmaceutical Co. Ltd, at the completion of his term in June 2014.

Chair-Elect Erica Mann, member of the Bayer HealthCare Executive Committee and
president of Bayer He ...

Chair-Elect Erica Mann, member of the Bayer HealthCare Executive Committee and
president of Bayer HealthCare's Global Consumer Care division (Photo: Business

The WSMI is a federation of around 50 member associations representing
manufacturers and distributors of non-prescription medicines and other
self-care products on all continents. WSMI aims to create and maintain an
international environment intended to improve the opportunities for people to
manage their own health through the responsible use of safe and effective
self-medication products. WSMI is a Non-Governmental Organization (NGO) in
official relations with the World Health Organization.

“I am honoured to be appointed the incoming WSMI Chair, particularly at a time
when consumer self-medication trends have never been stronger, and broadening
of non-prescription medicine availability is now under consideration in many
parts of the world. In this time of tightening public health budgets,
self-medication can empower consumers to take a greater role in the management
of their own healthcare while reducing unnecessary physician and hospital
visits,” said Mann. “Given today’s evolving regulatory and commercial
environments, there is a growing sense that our industry must strengthen its
engagement in policy issues on a global level, taking a consumer-centric
approach across countries and regions. I look forward to working with my WSMI
and industry colleagues, our regulators and policymakers, and other
stakeholders to build upon what WSMI has accomplished under Dr. Guo’s
leadership to ensure we can develop policies to support health care systems
with innovative self-medication offerings.”

Mann has been a member of the Bayer HealthCare Executive Committee and
responsible for the Consumer Care division since mid-March 2011. She began her
career in the pharmaceutical industry in 1982 at Eli Lilly & Company in South
Africa as a medical representative. This was followed by positions in
Marketing at Johnson & Johnson and Lederle Laboratories. In 1992 she was
appointed as Head of the Lederle Pharmaceutical Business in South Africa and
in 1994, Mann transferred to Wyeth as Managing Director for South Africa and
Sub-Equatorial Africa. She then held positions of increasing responsibility at
the company through 2009. In 2003, she was appointed Managing Director of the
Wyeth Australia and New Zealand Affiliate, where she introduced a range of
significant medicines and nutritionals. In April 2009 she assumed the role of
Senior Vice President for Wyeth’s Global Nutritional Business and in October
2009 she moved to the United States to join Pfizer upon its acquisition of
Wyeth where she was most recently President and General Manager for the
Nutrition Division and a member of Pfizer’s Senior Management Team.

In addition to currently serving as a WSMI board member, Mann has held
executive positions in several industry organizations, including the South
African Pharmaceutical Manufacturers’ Association (PMA) and Medicines
Australia, as well as the International Association of Infant Food

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the
world’s leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec
31, 2012) and is represented in more than 100 countries. More information at

Our online press service is just a click away:

Note to editors:

A photo in print quality can be downloaded from the internet at

Follow us on facebook:

Follow us on Twitter:

Forward-Looking Statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in Bayer’s public reports which are available
on the Bayer website at The company assumes no liability
whatsoever to update these forward-looking statements or to conform  them to
future events or developments.

Photos/Multimedia Gallery Available:



Bayer HealthCare
Tricia McKernan, +1 973-254-4993
Mobile: +1 973-462-0717
Press spacebar to pause and continue. Press esc to stop.